Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000

Ramin Artang; Camille Brod; Jorn Dalsgaard Nielsen

doi:10.1055/s-0042-1756699

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2022; 48(07): 808-813
DOI: 10.1055/s-0042-1756699

Review Article

Application of Activators Ecarin and Factor Xa in Thrombelastography for Measurement of Anticoagulant Effect of Direct Oral Anticoagulants Using TEG 5000

Ramin Artang

¹Essentia Health Heart and Vascular Center, Duluth, Minnesota, United States

²Department of Cardiology, Bispebjerg University of Copenhagen Hospital, Copenhagen, Denmark

,

Camille Brod

³University of Minnesota School of Medicine, Duluth, Minnesota, United States

,

Jorn Dalsgaard Nielsen

²Department of Cardiology, Bispebjerg University of Copenhagen Hospital, Copenhagen, Denmark

› Institutsangaben

Abstract

There are situations where monitoring direct oral anticoagulants (DOACs) would be useful, including bleedings and trauma. The thromboelastographic technique has proven useful in bleeding situations in trauma and heart surgery. The aim of this study was to examine the effect of DOACs on all currently commercially available conventional TEG®5000 assays as well as novel modified assay using Ecarin and human factor Xa (HFXa). Healthy male volunteers were given single dose of oral dabigatran 150 mg, rivaroxaban 20 mg, or apixaban 5 mg. Kaolin, RapidTEG, functional fibrinogen, PlateletMapping assay, and novel modified assays using Ecarin and HFXa were prepared. All TEG parameters were recorded. DOAC concentrations were correlated to the parameters with highest response to the DOAC effect. Sensitivity and negative predictive value of the parameter with highest response to DOAC concentration of 50 ng/mL was calculated. None of the conventional TEG assays demonstrated significant response to the effect on apixaban. Using Ecarin, reaction time R was strongly correlated with dabigatran concentrations. Using HFXa assay, R was strongly correlated with rivaroxaban and apixaban concentrations: r = 0.96, 0.84, and 0.86, respectively; p < 0.0001 for all. The R times obtained with the modified assays demonstrated strong sensitivity and negative predictive values for DOAC levels of ≥50 ng/mL. We have demonstrated that TEG®5000 can monitor the DOAC effect on hemostasis when the appropriate activator is used with significant correlation with DOAC concentrations. Larger clinical studies are warranted for correlation of TEG profile and clinical outcomes.

Keywords

thrombelastography - direct oral anticoagulants - platelets - dabigatran - rivaroxaban - apixaban

Volltext

Referenzen

References
1 Gonzalez E, Moore EE, Moore HB. et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg 2016; 263 (06) 1051-1059
2 Yang Z, Xie Z, Pei X, Quan X, Feng D. Effect of thrombelastography on timing of coronary artery bypass grafting. Exp Ther Med 2018; 16 (02) 579-584
3 Connors JM. Testing and monitoring direct oral anticoagulants. Blood 2018; 132 (19) 2009-2015
4 Artang R, Anderson M, Nielsen JD. Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers. Res Pract Thromb Haemost 2019; 3 (03) 391-396
5 Artang R, Dias JD, Walsh M. et al. Measurement of anticoagulation in patients on dabigatran, rivaroxaban, and apixaban therapy by novel automated thrombelastography. TH Open 2021; 5 (04) e570-e576
6 Ali JT, Daley MJ, Vadiei N. et al. Thromboelastogram does not detect pre-injury anticoagulation in acute trauma patients. Am J Emerg Med 2017; 35 (04) 632-636
7 Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA. Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med 2015; 139 (05) 665-673
8 Chandler WL. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 1995; 21 (Suppl 4): 1-6
9 Hartmann J, Walsh M, Grisoli A. et al. Diagnosis and treatment of trauma-induced coagulopathy by viscoelastography. Semin Thromb Hemost 2020; 46 (02) 134-146
10 Artang R, Frandsen NJ, Nielsen JD. Application of basic and composite thrombelastography parameters in monitoring of the antithrombotic effect of the low molecular weight heparin dalteparin: an in vivo study. Thromb J 2009; 7: 14
11 Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (03) 623-627
12 Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004; 329 (7458): 168-169
13 Hartert H. Blood clotting studies with thrombus stressography; a new investigation procedure [Article in German]. Klin Wochenschr 1948; 26 (37-38): 577-583
14 Gurbel PA, Bliden KP, Tantry US. et al. First report of the point-of-care TEG: a technical validation study of the TEG-6S system. Platelets 2016; 27 (07) 642-649
15 Groene P, Wagner D, Kammerer T. et al. Viscoelastometry for detecting oral anticoagulants. Thromb J 2021; 19 (01) 18
16 Oberladstätter D, Voelckel W, Schlimp C. et al. A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury. Anaesthesia 2021; 76 (03) 373-380
17 Hernandez-Juarez J, Espejo-Godinez HG, Mancilla-Padilla R. et al. Effects of rivaroxaban on platelet aggregation. J Cardiovasc Pharmacol 2020; 75 (02) 180-184
18 Bánovčin Jr P, Škorňová I, Samoš M. et al. Platelet aggregation in direct oral factor Xa inhibitors-treated patients with atrial fibrillation: a pilot study. J Cardiovasc Pharmacol 2017; 70 (04) 263-266